Jürgen Kuball



  • Leukemia

  • Allogeneic stem cell transplantation

  • Tumor immunology

  • GVHD




UMC Dept hematology

UMC Profile



Prof. Dr. Jürgen Kuball received his medical degree as hematologist at the University of Mainz, Germany, and was further trained at the Fred Hutchinson Cancer Center in Seattle, WA, USA. Prof. Kuball joined the Department of Hematology at the University Medical Center in Utrecht in The Netherlands in 2007 as hematologist and immunologist. He became a VIDI-laureate in 2010 and chairs the section applied & tumor-immunology within the laboratory of translational immunology. Since 2013 he is chairing the Department of Hematology (adults). His clinical activities are focusing on treating patients with hematological malignancies including stem cell transplantation. His clinical-translational efforts and patient care are driven by his role as Director of the Bone Marrow Transplantation Program at the University Medical Center Utrecht, as well as active member of the leukemia working party and stem cell working party of HOVON. His current laboratory activities are focusing on the understanding of innate immune cells and their receptors to recognize malignant cells and virally infected cells as well as the genetic engineering of a transplant.

Research topics

  • Chronic complications of immune interventions (GVHD)

  • Genetic engineering

  • Innate Immune System

  • Leukemia

  • Next generation allogeneic stem cell transplantations

Current External Activities

Board activities

  • EBMT Chair Legal and Regulatory Affairs Committee

  • HOVON General board

  • KWF adviesraad

  • Wetenschappelijke Raad Kika

  • Co-founder and scientific advisor of GADETA (www.gadeta.nl)


  • ASH

  • EBMT

  • EHA Member

  • HOVON Leukemia working party

  • HOVON SCT working party

Personal Fellowships & Awards

  • 2001 American Association of Cancer Research-GlaxoSmithKline Scholar in Cancer Research Award

  • 2005-2007 Stipendiat der Deutschen Krebshilfe

  • 2010 Team Science recognition award” of the Society for Immunotherapy of Cancer, University of Washington, USA

  • 2010 VIDI-Laureate ZonMW, The Netherlands

Scientific Publications


  • Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007;109(6):2331-8

  • Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau
    C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ,  
    Adams EJ, Scotet E, Kuball J. RhoB is a mediator of phosphoantigen recognition by Vγ9Vδ2
    T cell receptor. Cell Reports 2016;31:15(9):1973-1985  

  • Straetemans T, Gründer C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bönig H, Sebestyen Z, Kuball J. Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. Clin Cancer Res. 2015 ;21(17):3957-68.  

  • Scheper W, van Dorp S, Kersting S., Pietersma F, Lindemans C, Hol S, Heijhuurs S, Sebestyen Z, Grunder C, Marcu-Malina V, Marchant A, Donner C, Plachter B, Vermijlen D, van Baarle D, and Kuball J. (2013). gammadeltaT-cells elicited by CMV-reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013;27(6):1328-38

  • Grunder C, van DS, Hol S, Drent E, Straetemans T, Heijhuurs S, Scholten K, Scheper W, Sebestyen Z, Martens A, Strong R, Kuball J. gamma9 and delta2CDR3 domains regulate functional avidity of T-cells harboring gamma9delta2T-cell receptors. Blood 2012;120(26):5153-62

  • Kuball J, Hauptrock B, Malina V et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J.Exp.Med. 2009; 206: 463-475 (IF 12.5; 5Y 13.2) (J Kuball is corresponding author).

Projects and Grants

  • ZonMW 43400003: Redirecting T-cells by broadly tumor-reactive second-generation T-cellreceptors (1fte PostDoc, 1fte MTA including clinical trial and vector production; funded by Translational Gene Therapy Grant ZonMW)

  • VIDI-ZonMW 917.11.337: Linking innate and adaptive immune system by gammadeltaT-cells and their receptors in order to eradicate leukemia

  • UU 2013-6426: Re-directing T-cells by broadly tumor-reactive second generation TCRs: Isolation of engineered immune cells and extending toxicity experiments

  • EMCR2013-6409: Treatment of severe acute GVHD after allo-SCT with MSC+steroids or placebo+steroids (HOVON 112)

  • Vrienden van UMCU: Transposon

  • AICR 15-0049: Regulation of g9d2TCR mediated recognition by small GTPases

  • UU 2014-6790: TRANSIT: Towards the next generation of an engineered immune system

  • UU 2015-7601: Graft versus host disease: biomarkers and the local microenvironment within the context of a defined treatment

Clinical Trials



  • Transfer of T cell receptor-redirected T cells in patients with acute myeloid leukemia

Associated Team Members

  • Zsolt Sebestyen (Assistant Professor)

  • Moniek de Witte (Hematologist)

  • Trudy Straetemans (Post Doc)

  • Alberto Miranda Bedate (Post Doc)

  • Dennis Beringer (Post Doc)

  • Domenico Fasci (Post Doc)

  • Anke Janssen (PhD)

  • Anna Vyborova (PhD)

  • Eline van Diest (PhD)

  • Inez Johanna Gan (PhD)

  • Patricia Hernandez-Lopez (PhD)

  • Angelo Meringa (PhD)

  • Sabine Heijhuurs (Technician)

  • Tineke Aarts (Technician)

  • Astrid Cleven (Technician)

  • Sanne van Dooremalen (Technician)

  • Effrosyni Karaiskaki (Technician)